The challenges associated with the in vitro expansion of tumor-specific T cells boosted the creation of TCR-engineered lymphocytes; nonetheless, these cells have the limitation of recognizing only the tumor antigens that are presented by the major histocompatibility complex (MHC), also known as human leukocyte antigen (HLA) in humans [16]. Here, HLA-C is linked to neoplasm.